CD19 and congenital rubella syndrome: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occur at very high rates following CD19 CAR-T administration, with CRS occurring in greater than 50% of patients and at least 10–30% patients experiencing high grade ICANS [2].